Literature DB >> 21508857

Predicting dopamine D₂ receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis.

Hiroyuki Uchida1, Hiroyoshi Takeuchi, Ariel Graff-Guerrero, Takefumi Suzuki, Koichiro Watanabe, David C Mamo.   

Abstract

Measuring dopamine D₂ receptor occupancy levels using positron emission tomography (PET) is still widely unavailable. The objective of this study was to evaluate the accuracy of predicting D2 occupancy from the antipsychotic plasma level in patients with schizophrenia. Positron emission tomographic studies that measured plasma levels of antipsychotics and their corresponding D₂ occupancy levels were identified, using MEDLINE and EMBASE (last search: March 2010). Antipsychotics that were investigated in a total of 20 subjects or more were included. All data points for each antipsychotic were fit to a one-site binding model to estimate the total plasma concentration of each antipsychotic associated with a 50% occupancy (ED₅₀) of brain D₂ receptors. The mean prediction error and the root mean squared prediction error were used to measure the predictive performance of individual D₂ receptor occupancies from plasma drug levels derived from a one-site occupancy model using an ED₅₀ value calculated for each data point. A total of 34 treatment arms from 23 studies involving 281 subjects were included. The mean (95% confidence interval) prediction errors and root squared prediction errors were as low as 0.0 (-1.8 to 1.8) and 8.9 (7.6-10.2) for risperidone (n = 98); 0.0 (-3.5 to 3.5) and 15.1 (12.9-17.3) for clozapine (n = 75); -0.1 (-1.2 to 1.2), 0.0 (-1.9 to 1.9), and 4.6 (3.5-5.8) for olanzapine (n = 42); 0.1 (-3.4 to 3.5) and 9.9 (7.3-12.5) for haloperidol (n = 35); and -0.1 (-3.3 to 3.1) and 12.3 (8.8-15.7) for ziprasidone (n = 31), respectively. These findings suggest that D₂ occupancy of antipsychotics could be estimated with a high degree of accuracy using widely available plasma levels.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21508857     DOI: 10.1097/JCP.0b013e318218d339

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  19 in total

1.  Relationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone.

Authors:  E C Muly; J R Votaw; J Ritchie; L L Howell
Journal:  J Pharmacol Exp Ther       Date:  2012-01-03       Impact factor: 4.030

2.  Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial.

Authors:  Shinichiro Nakajima; Hiroyuki Uchida; Robert R Bies; Fernando Caravaggio; Takefumi Suzuki; Eric Plitman; Wanna Mar; Philip Gerretsen; Bruce G Pollock; Benoit H Mulsant; David C Mamo; Ariel Graff-Guerrero
Journal:  Schizophr Bull       Date:  2015-07-28       Impact factor: 9.306

3.  Plasma levels and estimated dopamine D2 receptor occupancy of long-acting injectable risperidone during maintenance treatment of schizophrenia: a 3-year follow-up study.

Authors:  Saeko Ikai; Takefumi Suzuki; Masaru Mimura; Hiroyuki Uchida
Journal:  Psychopharmacology (Berl)       Date:  2016-09-08       Impact factor: 4.530

4.  Predicting pharmacokinetic stability by multiple oral administration of atypical antipsychotics.

Authors:  Akihide Wakamatsu; Kazuo Aoki; Yojiro Sakiyama; Takashi Ohnishi; Makoto Sugita
Journal:  Innov Clin Neurosci       Date:  2013-03

5.  Determination of dopamine D₂ receptor occupancy by lurasidone using positron emission tomography in healthy male subjects.

Authors:  Dean F Wong; Hiroto Kuwabara; James Robert Brašić; Thomas Stock; Atul Maini; Emily G Gean; Antony Loebel
Journal:  Psychopharmacology (Berl)       Date:  2013-05-07       Impact factor: 4.530

Review 6.  Neuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia.

Authors:  Shinichiro Nakajima; Hiroyoshi Takeuchi; Eric Plitman; Gagan Fervaha; Philip Gerretsen; Fernando Caravaggio; Jun Ku Chung; Yusuke Iwata; Gary Remington; Ariel Graff-Guerrero
Journal:  Schizophr Res       Date:  2015-02-13       Impact factor: 4.939

7.  Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data.

Authors:  Hitoshi Sakurai; Robert R Bies; Scott T Stroup; Richard S E Keefe; Tarek K Rajji; Takefumi Suzuki; David C Mamo; Bruce G Pollock; Koichiro Watanabe; Masaru Mimura; Hiroyuki Uchida
Journal:  Schizophr Bull       Date:  2012-01-30       Impact factor: 9.306

8.  Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study.

Authors:  Takefumi Suzuki; Ariel Graff-Guerrero; Hiroyuki Uchida; Gary Remington; Fernando Caravaggio; Carol Borlido; Bruce Pollock; Benoit Mulsant; Vincenzo Deluca; Zahinoor Ismail; David Mamo
Journal:  Psychopharmacology (Berl)       Date:  2013-02-17       Impact factor: 4.530

Review 9.  Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature.

Authors:  William M Greenberg; Leslie Citrome
Journal:  Clin Pharmacokinet       Date:  2017-05       Impact factor: 6.447

10.  Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.

Authors:  Kazunari Yoshida; Robert R Bies; Takefumi Suzuki; Gary Remington; Bruce G Pollock; Yuya Mizuno; Masaru Mimura; Hiroyuki Uchida
Journal:  Schizophr Res       Date:  2014-02-01       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.